Human immunodeficiency virus (HIV) introduces its single-stranded RNA (ssRNA) genome into a cell in the reverse-transcription complex, which matures into the preintegration complex. This complex delivers reverse-transcribed HIV DNA to the nucleus for chromosomal integration. Few copies of HIV DNA integrate, leaving behind HIV DNA in the cytosol to be cleared by host enzymes. Although nucleic acids in the reverse-transcription complex might be shielded from nucleic acid sensors, viral DNA in the preintegration complex is accessible to exogenous endonucleases 1 and thus is potentially accessible to cytosolic sensors of innate immunity. The endoplasmic reticulum-associated SET complex, which contains three DNases (APE1, NM23-H1 and TREX1) and other proteins (SET, pp32 and HMGB2), binds to the HIV preintegration complex and protects the integrase-activated DNA ends from self attack in suicidal autointegration 2 . Suppressing the expression of any gene encoding a molecule of the SET complex increases autointegration and interferes with chromosomal integration. TREX1 is the most abundant 3′-5′ DNase in cells 2 . Treatment with TREX1-specific small interfering RNA (siRNA) inhibits HIV replication more profoundly than do siRNAs specific for other SET complex components, decreasing viral production by a log 2 . TREX1 mutations are associated with inflammatory and autoimmune diseases, including Aicardi-Goutieres syndrome, chilblain lupus, and systemic lupus erythematosus, some of which have more type I interferon [3] [4] [5] . TREX1 binds to transfected immunostimulatory DNA, and Trex1 −/− cells accumulate cytoplasmic DNA derived from endogenous retroelements, which activates interferon expression dependent on interferon-regulatory factor 3 (IRF3) [6] [7] [8] . Like HIV, endogenous retroelements undergo cytoplasmic reverse transcription. We therefore investigated whether HIV might use TREX1 to avoid triggering antiviral innate immunity.
RESULTS

TREX1 inhibits interferon production in response to HIV
We first compared the replication of HIV and the expression and secretion of type I interferons and inflammatory cytokines after infecting Trex1 +/+ (wild-type) and Trex1 −/− mouse embryonic fibroblasts (MEFs) with vesicular stomatitis virus G (VSV-G)-pseudotyped HIV-luciferase virus, a single-round virus that does not produce infectious virus and has a nearly full-length HIV genome (lacking the gene encoding the envelope protein and with replacement of the gene encoding negative factor (Nef) with a gene encoding luciferase). This virus can infect MEFs, integrate and execute long terminal repeat (LTR)-driven expression of the luciferase reporter 9 . After being infected with HIV-luciferase, Trex1 −/− MEFs had luciferase activity one tenth that of wild-type MEFs (Fig. 1a) . Uninfected Trex1 −/− MEFs constitutively expressed slightly more interferon-β (IFN-β) mRNA than did wild-type MEFs (Fig. 1b) . In Trex1 −/− cells, HIV infection induced both IFN-β mRNA (~100-fold more than that of uninfected cells) and interleukin 6 (IL-6) mRNA (~10-fold more than that of uninfected cells; Fig. 1b,c) . Neither IFN-β nor IL-6 was induced by HIV infection of wild-type MEFs. HIV did not induce IL-1β, IFN-α or IFN-γ in wild-type or Trex1 −/− MEFs (data not shown). IFN-β was secreted, as assessed by enzyme-linked immunoassay (ELISA) of cultured supernatants (Fig. 1d) . Nevirapine, which inhibits HIV 1 0 0 6 VOLUME 11 NUMBER 11 NOVEMBER 2010 nature immunology A r t i c l e s reverse transcription, inhibited the expression of IFN-β and IL-6 in response to HIV in Trex1 −/− cells, but the integrase inhibitor raltegravir, which acts after the synthesis of HIV DNA, did not ( Fig. 1b-f) ; this suggested that reverse-transcribed HIV DNA, rather than genomic RNA, was triggering the response. Treatment of the virus with DNase did not alter the IFN-β response to HIV-luciferase in Trex1 −/− cells (data not shown), which eliminated concerns that carryover of plasmid DNA was responsible for the induction of IFN-β. Virus-like particles lacking genomic RNA and heat-inactivated HIV also did not trigger IFN-β expression (Fig. 1g) , which suggested that viral nucleic acid and an infectious virus were required. Because nonproductive autointegrated (autointegrant) DNA accumulates when TREX1 is inhibited by siRNA 2 , autointegrant DNA might have been triggering IFN-β. However, although only the reverse-transcription inhibitor suppressed IFN-β production, both the reverse-transcription inhibitor and integrase inhibitor blocked the production of autointegrants (Fig. 1h) . These results suggest that the HIV-stimulated production of IFN-β in Trex1 −/− MEFs was activated by HIV DNA other than autointegrant DNA.
HIV-stimulated interferon expression is IRF3 dependent IFN-β expression induced by transfected immunostimulatory DNA or endogenous retroelements in Trex1 −/− cells is mediated by the transcription factor IRF3 (refs. 6,7). To investigate whether IRF3 also activates HIV-induced expression of IFN-β, we compared IFN-β mRNA and HIV infectivity in wild-type, Trex1 −/− and Trex1 −/− Irf3 −/− MEFs. Lack of IRF3 completely inhibited IFN-β induction (Fig. 2a) . HIV-luciferase activity was also partially restored in Trex1 −/− Irf3 −/− cells (Fig. 2b) . Therefore, the IFN-β induction in response to HIV in Trex1 −/− cells was mediated by IRF3. Autointegration in the absence of Trex1 was indistinguishable in Trex1 −/− and Trex1 −/− Irf3 −/− cells (Fig. 2c) , which suggested that autointegration is not altered by endogenous IFN-β production and that the two effects of TREX1 on HIV infection (blocking autointegration and inhibiting IFN-β induction) operate independently. Similarly, in human 293T embryonic kidney cells, TREX1-specific siRNA resulted in higher HIV-induced luciferase expression from the IFNB promoter, whereas siRNAs specific for some other SET complex genes had no effect on IFN-β expression (Supplementary Fig. 1 ). Therefore, protection from IFN-β activation involves TREX1 but not the entire SET complex.
Activation of IRF3 triggers its nuclear translocation. To verify the role of IRF3 in HIV-induced IFN-β expression in Trex1 −/− cells, we monitored IRF3 localization by confocal microscopy. IRF3 was cytoplasmic in uninfected wild-type and Trex1 −/− MEFs (Fig. 2d) . After infection with VSV-G-pseudotyped HIV expressing green fluorescent protein (HIV-GFP) at a multiplicity of infection (MOI) of 1, 68% of wild-type MEFs were infected, as assessed by GFP expression. At the same MOI, viral entry was similar in Trex1 −/− cells (assessed by quantitative RT-PCR for HIV genomic RNA; data not shown), but GFP expression was much lower (Fig. 2e) . IRF3 remained cytoplasmic in 100% of wild-type cells but translocated into the nucleus in 44% of Trex1 −/− cells (Fig. 2d) . These data confirm that the HIV-stimulated IFN-β response is IRF3 dependent and indicate the involvement of a cytosolic detection pathway. Likewise, these findings suggest that HIV DNA is not sensed by Toll-like receptor 9, which is contained in endosomes and activates type I interferon through IRF7 rather than IRF3 (refs. 10,11) .
HIV reverse transcripts accumulate in Trex1 −/− cells To gain insight into how TREX1 suppresses HIV-stimulated IFN-β induction, we measured cytosolic HIV DNA and IFN-β mRNA in wild-type and Trex1 −/− cells during infection with HIV-GFP (MOI = 1; Fig. 3a) . We also measured incoming HIV genomic RNA at 2 h and 5 h after infection to verify that wild-type and Trex1 −/− cells were infected with the same amount of virions (Fig. 3b) . Cytosolic HIV DNA steadily increased for the first 20 h after infection and then achieved a three-to fourfold higher plateau in Trex1 −/− cells than in wild-type cells. In wild-type cells, IFN-β mRNA remained at baseline. In Trex1 −/− cells, IFN-β mRNA was induced but lagged behind the accumulation of HIV DNA, first increasing 12 h after infection. (Fig. 3c,d ). Although cytosolic HIV DNA was about tenfold more abundant in Trex1 −/− MEFs than in wild-type MEFs, HIV DNA integration was lower in Trex1 −/− cells than in wild-type cells (Fig. 3e) , which suggested that most of the HIV DNA that accumulated in Trex1 −/− cells did not contribute to productive infection. (Fig. 3g) . Infection with HIV-luciferase was inhibited similarly in cells incubated with mouse IFN-β at a concentration of 100 pg/ml or with conditioned medium from HIV-infected Trex1 −/− MEFs, which contained IFN-β at a concentration of 120 pg/ml (Figs. 1d and 3h) . These findings suggest that IFN-β is the main secreted antiviral factor.
To pinpoint which stage(s) of HIV replication IFN-β blocks, we treated wild-type MEFs with mouse IFN-β and measured HIV DNA synthesis, two-LTR circle formation and integration. To assess Fig. 2 ). Higher doses of IFN-β blocked nearly all early stages of HIV replication in single-round infection. Thus, secreted IFN-β inhibits multiple steps in the early phase of HIV infection.
TREX1 digestion of HIV DNA blocks interferon induction
To identify which HIV nucleic acids trigger IFN-β expression, we transfected wild-type and Trex1 −/− MEFs with synthetic 100-base pair oligonucleotides containing sequences from the HIV gene encoding the group-associated antigen (Gag) protein, which corresponded to HIV nucleic acids in the cytosol during reverse transcription (ssRNA to represent genomic RNA, RNA-DNA hybrids, single-stranded DNA (ssDNA) and double-stranded DNA (dsDNA)), and measured IFN-β mRNA 6 h later by quantitative RT-PCR (Fig. 4a,b) . All DNAcontaining oligonucleotides induced more IFN-β in Trex1 −/− MEFs than in wild-type MEFs, but ssRNA did not. We found that ssDNA elicited the largest difference (~200-fold more IFN-β for ssDNA compared with 20-to 40-fold more for dsDNA and 2-to fourfold for RNA-DNA duplexes). None of the oligonucleotides induced IFN-β in Trex1 −/− Irf3 −/− MEFs (data not shown), which supported the idea of IRF3's role in signaling the presence of these cytosolic nucleic acids. Although synthetic oligonucleotides may not completely mimic native HIV products of reverse transcription, these data are consistent with the known enzymatic preference of TREX1 for ssDNA substrates rather than dsDNA substrates 16 . To determine whether transfected oligonucleotides accumulated in Trex1 −/− cells as HIV DNA does during infection, we quantified cytosolic DNA after transfection of ssDNA or dsDNA containing the sequence encoding Gag or after HIV infection. Cytosolic DNA was four-to sixfold more abundant in Trex1 −/− MEFs than in wild-type MEFs when measured 3 h after transfection or 10 h after infection (Fig. 4c) . We repeated this experiment with human fibroblasts derived from a patient with chilblain lupus that expressed either wild-type TREX1 or mutant TREX1 (with substitution of asparagine for aspartic acid at position 18 (D18N)). D18N is a substitution in a highly conserved Mg 2+ -binding site in the Exo1 domain of TREX1 that eliminates exonuclease activity and interferes with the enzymatic activity of the wild-type-mutant TREX1 heterodimer 3, 17 . Cells expressing the D18N mutant also accumulated all DNA species introduced by infection or transfection (Fig. 4c) . The accumulation of HIV DNA in Trex1 −/− or TREX1 mutant cells is consistent with a published report showing that the cytosol of Trex1 −/− cells has more ssDNA derived from endogenous retroelements 7 . These results suggest that TREX1 suppresses IFN-β induction by digesting cytosolic DNA.
For further evidence that TREX1 is responsible for removing extraneous cytosolic HIV DNA, we assessed whether TREX1 interacted with HIV DNA during infection with wild-type HIV strain IIIB. We infected HeLa-CD4 cells expressing Flag-tagged TREX1 with HIV IIIB for 10 h, then obtained cytosolic extracts of these cells and immunoprecipitated proteins with antibody to Flag (anti-Flag) or immunoglobulin G (control antibody). We assessed enrichment for HIV DNA and RNA encoding Gag in the precipitates by quantitative PCR or quantitative RT-PCR, respectively. Anti-Flag immunoprecipitated threefold more HIV DNA than did the immunoglobulin G control, but there was no enrichment for HIV RNA (Fig. 4d) , which confirmed that HIV DNA binds to TREX1 and is its 'preferred' target.
To determine whether the enzymatic activity of TREX1 is needed to enhance HIV infection, we assessed whether expression of wild-type or D18N TREX1 in Trex1 −/− cells could restore HIV-luciferase infectivity (Fig. 4e) . Wild-type TREX1 partially restored HIV infection, but the enzymatically inactive D18N mutant had no effect, which indicated that TREX1's exonuclease activity is needed for both inhibiting autointegration and blocking IFN-β induction. We also measured the accumulation of HIV DNA in wild-type and Trex1 −/− cells transfected with GFP-tagged wild-type or D18N TREX1. As shown above (Fig. 3) , Trex1 −/− cells accumulated about five times more cytosolic HIV DNA than did wild-type cells. The excess HIV DNA was completely eliminated by expression of GFP-tagged wild-type TREX1 but not by expression of GFP-tagged D18N TREX1 (Fig. 4f) . These results suggest that TREX1 metabolizes cytosolic HIV DNA. Because overexpressing GFP-tagged wild-type TREX1 did not diminish HIV DNA abundance below that in an infected wild-type cell, TREX1 may not have access to all HIV DNA products.
HIV activates interferon in TREX1-deficient human cells
Most experiments in this study reported above used mouse Trex1 −/− cells to take advantage of their complete lack of TREX1, in contrast to the incomplete inhibition afforded by siRNAs. To investigate whether our findings were physiologically relevant during HIV infection of primary human immune cells, we used siRNA to suppress TREX1 alone or both TREX1 and IRF3 in monocyte-derived macrophages (MDMs) from two human donors. At 3 d after siRNA treatment, we infected siRNA-treated cells, which had 60-80% less TREX1 and/or IRF3 mRNA than did cells treated with control siRNA, with the BaL strain of HIV (Fig. 5a-c) . At 24 h after infection, cytosolic HIV DNA was about fourfold higher in samples treated with siRNA specific for TREX1 or for both TREX1 plus IRF3 than in samples treated with control siRNA. HIV replication and spreading in cultures of macrophages treated with TREX1-specific siRNA was one fourth to one half that in control cells, as assessed by measurement of HIV Gag p24 antigen in the medium. When expression of both IRF3
and TREX1 was suppressed, HIV replication was partially restored (Fig. 5d) , which suggested that IRF3-dependent induction of IFN-β contributed to the inhibition of HIV replication caused by TREX1-specific siRNA. Consistent with that idea, expression of both IFN-α and IFN-β mRNA increased up to tenfold in macrophages treated with TREX1-specific siRNA, but not in those treated with control siRNA or with TREX1-specific and IRF3-specific siRNAs (Fig. 5e) .
We obtained similar results after transfection with TREX1-specific siRNA into human peripheral blood CD4 + T cells infected with HIV IIIB (Fig. 5f-l) . In T cells treated with TREX1-specific siRNA, HIV DNA accumulated in the cytosol and the expression of both IFN-α and IFN-β was induced. TREX1-specific siRNA similarly resulted in less HIV production, as measured by flow cytometry analysis of intracellular p24. Both the number of p24 + cells and p24 mean fluorescence intensity were lower. Therefore, TREX1 deficiency resulted in less HIV replication and spreading in culture. The magnitude of these effects increased with the amount of siRNA transfected and the extent of TREX1 suppression. Therefore, during infection of primary human cells with wild-type HIV, TREX1 suppresses HIV-induced IFN-β activation through IRF3 to promote HIV replication.
HIV DNA signals via STING, TBK1 and IRF3
To investigate the pathway triggered by HIV DNA, we treated Trex1 −/− MEFs with siRNAs targeting selected genes linked to DNA-stimulated induction of interferon and examined the effect on HIV-stimulated IFN-β expression (Fig. 6a,b) . Inhibiting a gene (Fig. 6b) [24] [25] [26] [27] , did not suppress HIV-stimulated expression of IFN-β, which suggested that an unknown sensor detects HIV DNA or that multiple known DNA sensors might function redundantly. Additional experiments confirmed that the RNA polymerase III-RIG-I-MAVS DNA-detection pathway 22, 23 was not involved in HIV-stimulated induction of interferon (Supplementary Fig. 3 ). However, siRNA specific for the gene encoding another membraneassociated adaptor, STING (also known as MITA and ERIS [28] [29] [30] ), which has been identified as mediating innate immune responses to cytosolic DNA 28, 29 , inhibited HIV-stimulated expression of IFN-β (Fig. 6b) . STING is phosphorylated by the kinase TBK1 (refs. 29,31). We found that siRNA specific for the genes encoding STING, IRF3 or TBK1 did not affect cytosolic accumulation of HIV DNA in Trex1 −/− MEFs (Fig. 6c) , which suggested that they act downstream of DNA sensing. Thus, HIV DNA is detected by a pathway that signals through STING, TBK1 and IRF3 and does not involve any known DNA sensor (Supplementary Fig. 4) . HMGB2, but not its homolog HMGB1, associates with TREX1 in the cytosolic SET complex 32 . Treatment of HIV-infected wild-type and Trex1 −/− MEFs with Hmgb2-specific siRNA enhanced IFN-β expression (Fig. 6b) , which suggested that HMGB2 inhibits the response to cytosolic HIV DNA. However, treatment with Hmgb2-specific siRNA did not result in more cytosolic HIV DNA in Trex1 −/− MEFs than in those treated with control siRNA (Fig. 6c) , which suggested that HMGB2 might act downstream of the recognition of HIV DNA. HMGB proteins repress the transcription of many genes, including proinflammatory genes, such as TNF [33] [34] [35] . To determine whether HMGB2 regulates IFNB transcription, we transfected HMGB2-specific siRNA into 293T cells expressing a luciferase reporter plasmid driven by the IFNB promoter. IFN-β-luciferase expression was about twofold higher in cells treated with HMGB2-specific siRNA than in those treated with control siRNA in response to poly(dA:dT) or MAVS overexpression (Supplementary Fig. 5 ), which suggested that HMGB2 inhibits IFNB expression, either directly or indirectly, though its promoter, but acts downstream of DNA sensing. To determine whether HMGB2 has a role in the removal of cytosolic HIV DNA or HIV-stimulated expression of interferon in primary human MDMs, we suppressed HMGB2 alone or together with TREX1.
HMGB2-specific siRNA on its own did not result in more cytosolic HIV DNA. However, unlike results obtained with Trex1 −/− MEFs, treatment of human macrophages with HMGB2-and TREX1-specific siRNA resulted in significantly more accumulation of cytosolic HIV DNA than did treatment with TREX1-specific siRNA alone (P < 0.05). Treatment with HMGB2-specific siRNA led to HIV-stimulated expression of IFN-α and IFN-β, but did not induce interferon expression in uninfected cells (data not shown); this was significantly greater than that induced by TREX1-specific siRNA alone and was not enhanced by treatment with both siRNAs (P < 0.05). These results suggest that HMGB2 may act together with TREX1 to remove HIV DNA from the cytoplasm (model, Supplementary Fig. 4) . Further work is needed to elucidate the role of HMGB2 in suppressing HIV DNA-stimulated induction of interferon, but these results suggest that HMGB2 might act at multiple points (by recognizing and/or helping eliminate cytosolic DNA and suppressing the IFNB promoter).
DISCUSSION
HIV infection of its main target cells, macrophages and CD4 + T cells, does not induce cell-autonomous interferons 36 . We have shown here that the host cytoplasmic exonuclease TREX1 helps HIV evade innate immunity by digesting reverse transcripts that are not imported into the nucleus and would otherwise induce interferons. When TREX1 was inhibited by RNAi, HIV infection of primary cells triggered expression and secretion of type I interferon. The HIV-stimulated interferon response in cells deficient in TREX1, like the response to endogenous retroelement DNA and transfected DNA 7 , was IRF3 dependent. We found that interferon induction in TREX1-deficient cells was blocked by the expression of enzymatically active TREX1 or by cosuppression of IRF3 expression to interrupt interferon signaling. HIV-stimulated innate immune signaling also required STING and TBK1. On the basis of our siRNA experiments, we conclude that none of the known DNA sensors was involved. Therefore, our working model of the innate immune pathway activated by cytosolic HIV DNA starts with an unknown sensor (that may 'preferentially' recognize ssDNA) that signals through STING, TBK1 and IRF3 to activate interferon expression.
Type I interferons inhibit HIV replication at multiple steps in the early phase of its life cycle and thereby suppress viral spreading. Failure to induce antiviral interferons in infected T cells and macrophages may promote transmission by allowing the virus to spread from the initial nidus of infection to neighboring cells in genital tissue. However, assessing the importance of TREX1 in transmission will require efficient methods for inhibiting TREX1 expression in vivo in the immune cells that HIV infects. Such methods are not yet available but are being developed. We used an MOI of 1 to achieve a reasonable frequency of infected cells. As cytoplasmic accumulation Viral concentrations may reach a high MOI locally during the replicative burst that occurs in the genital tract during transmission, when a strong intrinsic antiviral immune response might prevent dissemination 37 . Other settings of high viral concentration might be activated lymph nodes or gut-associated lymphoid tissues. We did not determine whether TREX1 affects interferon production by plasmacytoid DCs, the main source of type I interferon during HIV infection. HIV replication is inefficient in DCs. Interferon stimulation in plasmacytoid DCs seems to be triggered mostly by endocytosed virus, whose genomic RNA is recognized by Toll-like receptor 7 in endosomes 38 . Productive HIV infection of macrophages and T cells, however, involves fusion of the viral membrane with the cell membrane and direct uncoating of the viral capsid into the cytosol, bypassing the endosomal compartment and Toll-like receptor signaling. Nonetheless, it will be important to determine whether TREX1 modulates interferon signaling in plasmacytoid DCs.
We found that HIV-stimulated activation of interferon in Trex1 −/− cells was eliminated by treatment of infected cells with an inhibitor of reverse transcription but not by treatment with an integrase inhibitor, which suggests that HIV DNA, not genomic RNA, is the nucleic acid that triggers innate immunity. The nucleic acid most sensitive to TREX1 activity is ssDNA, and therefore ssDNA is probably its main substrate. IFN-β mRNA is normally detected 6-8 h after transfection of immunostimulatory DNA or infection with a DNA virus 6, 22, 39 . After HIV infection, interferon mRNA is not detected until 12 h after infection; the lag in IFN-β expression is probably due to the time needed to complete reverse transcription. The rapid decrease in IFN-β mRNA expression after it reaches its peak value suggests that a cell-autonomous secondary mechanism tempers the innate immune response that, if unchecked, could be harmful to the host. Some HIV DNA accumulated in the cytoplasm of HIV-infected cells, even when TREX1 was normally expressed, but it did not activate interferon expression. A cytoplasmic DNA threshold, which might vary in different cell types, may need to be exceeded to trigger innate immunity.
HMGB proteins have been proposed as innate immune sentinel proteins that facilitate nucleic acid recognition by sensors of RNA and DNA 21 . Here, experiments with HMGB2-specific siRNA demonstrated the opposite effect: HMGB2 helped suppress interferon induction by HIV in human cells. Although RNAi of Hmgb2 in Trex1 −/− MEFs did not result in more cytosolic HIV DNA, RNAi of HMGB2 in human macrophages that were also treated with TREX1-specific siRNA resulted in enhanced cytosolic HIV DNA and induction of IFN-α and IFN-β. Therefore, HMGB proteins may have a more complex role in innate immunity than originally suggested. In their role as sentinels for foreign nucleic acids, they may facilitate the recognition of nucleic acids both by sensors that trigger innate immune responses and by proteins, such as TREX1, that inhibit interferon induction. Therefore, the net effect of a lower abundance of HMGB proteins could be either to inhibit interferon induction (as reported before 21 ) or to enhance it, as shown here. We also found that HMGB2 acted downstream of nucleic acid sensing at the IFNB promoter to suppress IFNB transcription, which adds another layer of complexity. This transcriptional effect extended to non-HIV innate immune stimuli (the synthetic dsDNA poly(dA:dT) and overexpression of MAVS). In the study noted above 21 , IFN-β expression stimulated by poly(dA:dT) was lower in Hmgb2 −/− MEFs than in wild-type MEFs, whereas we found the opposite effect with RNAi of Hmgb2. The apparent discrepancy between those results 21 and ours could be due to a difference in the consequences of complete or partial Hmgb2 elimination, especially if HMGB2 operates at multiple steps in interferon induction.
In many of our experiments we used genetically deficient mouse cells to demonstrate that TREX1 helps HIV evade detection by the innate immune system and to define the HIV DNA-stimulated interferon signaling pathway. Knockout mouse cells are powerful tools for HIV research 9, 40, 41 . Once the block in the entry into mouse cells is overcome by VSV-G pseudotyping, most early steps of HIV replication, including reverse transcription, integration and LTR-driven transcription, are similar in human and mouse cells. Furthermore, human TREX1 is 73.3% identical to its mouse homolog in amino acid sequence, and is 71.4%, 100% and 86.7% identical to its mouse homolog in its three exonuclease motifs 16 . Human and mouse TREX1 have the same enzymatic activity and can substitute for each other 16 . Therefore, mouse cells are well suited for the study of TREX1 function in HIV replication. Nonetheless, human immune cells susceptible to HIV can differ from MEFs in their ability to activate innate immune pathways. For example, IFN-α was induced by HIV in human immune cells but not in MEFs. The differences in the role of HMGB2 in the accumulation of HIV DNA in human macrophages and MEFs may be another case in point. We confirmed all key findings in primary human cells, including HIV DNA accumulation, interferon induction and inhibition of HIV replication when TREX1 was inhibited by RNAi, and efficient rescue by cosuppression of IRF3 expression.
Our data shed light on the fate of nonproductive or nonintegrated HIV DNA in the cell. At an MOI of 1, HIV infection produced many reverse transcripts (although only one per incoming genomic RNA), but very few copies managed to integrate into the host chromosome. The remaining HIV DNA was cleared by TREX1, as cytosolic HIV DNA built up when TREX1 function was deficient or inhibited and was removed after expression of enzymatically active TREX1. As a consequence, wild-type TREX1 fully restored HIV infectivity in Trex1 −/− MEFs, and the D18N mutant failed to do so. Other host nucleases might also help digest cytosolic HIV DNA. It is unclear why the excess HIV DNA that accumulated in Trex1 −/− cells did not lead to more chromosomal integration. Sequencing these excess HIV DNAs may show whether they are able to integrate and what prevents them from integrating. These excess HIV DNAs may be mostly nonproductive products of reverse transcription.
TREX1 promotes HIV replication in the following two ways: it inhibits autointegration 2 , and it suppresses the interferon response. Several models might explain the dual effects of TREX1 on HIV DNA. One possibility is that TREX1 might sort productive versus nonproductive HIV products of reverse transcription. Reverse transcription of HIV is error prone and often produces incomplete products. TREX1 recognizes ssDNA or dsDNA with single-strand overhangs, the kind of DNA in failed products of reverse transcription. TREX1 might bind to HIV DNA nonspecifically in the cytosol but as an exonuclease can only efficiently digest HIV DNA that contains broken ends or single-strand overhangs. HIV integrase binds to the ends of reverse transcripts that are capable of chromosomal integration and might protect them from digestion by TREX1. Incomplete products of reverse transcription, however, would not bind integrase and therefore would be susceptible to degradation by TREX1. Autointegration requires the full-length product of reverse transcription and active DNA ends bound by integrase, which catalyzes autointegration. Although TREX1 probably binds to full-length integration-competent products, as well as to transcripts that are not competent for integration, its exonuclease activity might be inhibited A r t i c l e s in the full-length transcript by lack of some DNA feature that facilitates digestion (such as shielding by integrase). Another possibility is that TREX1 is inhibited by components of the SET complex that also bind to the HIV preintegration complex 2 . Another DNase in the SET complex, NM23-H1, is inhibited by SET protein and is activated only when granzyme A cleaves SET 42 . TREX1 is an abundant protein that is not exclusively present in the SET complex. Two subpopulations of TREX1 could be involved in different actions: the SET complex-associated TREX1 inhibits autointegration, whereas TREX1 outside the SET complex is enzymatically active and removes excess HIV DNA. This model would also explain why siRNAs directed against genes encoding most other molecules of the SET complex do not induce interferon but do protect against autointegration. Further studies are needed to test these ideas.
Mutations in TREX1 that interfere with the enzymatic function or localization of TREX1 are associated with systemic lupus erythematosus and other autoimmune and/or inflammatory diseases [3] [4] [5] . Patients with systemic lupus erythematosus are underrepresented in HIV-infected populations 43 . It would be worth evaluating whether TREX1 polymorphisms or autoimmune diseases are associated with less HIV transmission or a more benign disease course. The innate immune pathway identified in this study will improve understanding of how HIV intersects with innate immunity and may also shed light on autoimmune and inflammatory syndromes linked to TREX1 mutation.
METHODS
Methods and any associated references are available in the online version of the paper at http://www.nature.com/natureimmunology/.
